Clinical Trial Detail

NCT ID NCT04404140
Title A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Recruitment Recruiting
Gender male
Phase Phase I
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

prostate adenocarcinoma

Therapies

Atezolizumab + Docetaxel + Ipatasertib

Age Groups: adult senior

No variant requirements are available.